{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:15:40Z","timestamp":1761513340490},"reference-count":61,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.vaccine.2013.08.032","type":"journal-article","created":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T23:36:06Z","timestamp":1377646566000},"page":"1624-1629","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Current barriers, challenges and opportunities for the development of effective STI vaccines: Point of view of vaccine producers, biotech companies and funding agencies"],"prefix":"10.1016","volume":"32","author":[{"given":"Betty","family":"Dodet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.08.032_bib0005","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.vaccine.2013.07.087","article-title":"Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines","volume":"32","author":"Gottlieb","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0010","series-title":"Vaccines","first-page":"157","article-title":"The vaccine industry","author":"Douglas","year":"2012"},{"year":"2013","series-title":"The vaccine industry \u2013 an overview","author":"Prifti C","key":"10.1016\/j.vaccine.2013.08.032_bib0015"},{"year":"2013","series-title":"The history of vaccines","author":"College of Physicians of Philadelphia","key":"10.1016\/j.vaccine.2013.08.032_bib0020"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0025","unstructured":"European Vaccine Initiative (EVI). Stages of vaccine development, <http:\/\/www.euvaccine.eu\/vaccines-diseases\/vaccines\/stages-development>."},{"key":"10.1016\/j.vaccine.2013.08.032_bib0030","unstructured":"Sanofi Pasteur. The vaccine development cycle, http:\/\/www.sanofipasteur.com\/?codeRubrique=31. (accessed 28.04.2013)."},{"year":"2012","series-title":"Vaccine fact book","author":"PhRMA","key":"10.1016\/j.vaccine.2013.08.032_bib0035"},{"year":"2012","series-title":"GSK \u2013 Annual report","key":"10.1016\/j.vaccine.2013.08.032_bib0040"},{"year":"2005","series-title":"Making Markets for Vaccines? Ideas to action. The report of the Center for Global Development Advance Market Commitment Working Group","author":"Levine","key":"10.1016\/j.vaccine.2013.08.032_bib0045"},{"year":"2009","series-title":"Report to Congress \u2013 Coordinated Strategy to Accelerate Development of Vaccines for Infectious Diseases","author":"USAID","key":"10.1016\/j.vaccine.2013.08.032_bib0050"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0055","unstructured":"Plotkin S. How companies choose projects, <http:\/\/www.iom.edu\/\u223c\/media\/Files\/Activity%20Files\/PublicHealth\/NatVaxPlan\/IOM2008PrioritiesPanel3_pptReadOnly.pdf> [accessed 28.04.13]."},{"issue":"9","key":"10.1016\/j.vaccine.2013.08.032_bib0060","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.2105\/AJPH.2005.074583","article-title":"Assembling a global vaccine development pipeline for infectious diseases in the developing world","volume":"96","author":"Serdobova","year":"2006","journal-title":"Am. J. Public Health"},{"year":"2006","series-title":"The vaccine industry: does it need a shot in the arm? National Health Policy Forum","author":"Salinsky","key":"10.1016\/j.vaccine.2013.08.032_bib0080"},{"year":"2013","series-title":"Vaccine research","author":"NIH\/NIAID","key":"10.1016\/j.vaccine.2013.08.032_bib0070"},{"year":"2013","series-title":"Vaccine Research Center (VRC)","author":"NIH\/NIAID","key":"10.1016\/j.vaccine.2013.08.032_bib0075"},{"year":"2013","series-title":"About NIAID","author":"NIH\/NIAID","key":"10.1016\/j.vaccine.2013.08.032_bib0065"},{"year":"2013","series-title":"Immunization basics","author":"USAID","key":"10.1016\/j.vaccine.2013.08.032_bib0085"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0090","unstructured":"European Vaccine Initiative (EVI). <http:\/\/www.euvaccine.eu\/>; 2013 [accessed 28.04.13]."},{"key":"10.1016\/j.vaccine.2013.08.032_bib0095","unstructured":"Transvac. <http:\/\/www.transvac.org\/about-transvac>; 2013 [accessed 28.04.13]."},{"year":"2013","series-title":"Advanced immunization technologies","author":"Aditec","key":"10.1016\/j.vaccine.2013.08.032_bib0100"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0105","unstructured":"GAVI Alliance. <http:\/\/www.gavialliance.org\/about\/mission\/>; 2013 [accessed 28.04.13]."},{"key":"10.1016\/j.vaccine.2013.08.032_bib0110","unstructured":"Bill & Melinda Gates Foundation. <http:\/\/www.gatesfoundation.org\/>; 2013 [accessed 28.04.13]."},{"key":"10.1016\/j.vaccine.2013.08.032_bib0115","unstructured":"IFFIm. <http:\/\/www.iffim.org\/>; 2013 [accessed 28.04.13]."},{"year":"2013","series-title":"Advanced market commitments for vaccines","author":"WHO","key":"10.1016\/j.vaccine.2013.08.032_bib0120"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0125","series-title":"Vaccines","first-page":"3554","article-title":"Herpes simplex virus vaccines","author":"Stanberry","year":"2012"},{"issue":"1","key":"10.1016\/j.vaccine.2013.08.032_bib0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N Engl J Med"},{"issue":"June","key":"10.1016\/j.vaccine.2013.08.032_bib0135","first-page":"963513","article-title":"Chlamydia trachomatis vaccine research through the years","author":"Schauttet","year":"2011","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.vaccine.2013.08.032_bib0140","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nrmicro2668","article-title":"The development of vaccines: how the past led to the future","volume":"9","author":"Plotkin","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0145","article-title":"Current status and prospects for development of an HSV vaccine","author":"Johnston","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0150","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.vaccine.2013.08.020","article-title":"Development status and future vaccines from Chlamydia trachomatis infections","volume":"32","author":"Timms","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0155","article-title":"Vaccines against gonorrhea: current status and future challenges","author":"Jerse","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0160","article-title":"Current status and prospects for development of a vaccine against Trichomonas infections","author":"Smith","year":"2013","journal-title":"Vaccine"},{"issue":"5 (Suppl)","key":"10.1016\/j.vaccine.2013.08.032_bib0165","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/0002-9394(67)94155-4","article-title":"Trachoma vaccine studies in monkeys","volume":"63","author":"Wang","year":"1967","journal-title":"Am J Ophthalmol"},{"issue":"5 (Suppl)","key":"10.1016\/j.vaccine.2013.08.032_bib0170","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/0002-9394(67)94158-X","article-title":"Field trial of a monovalent and of a bivalent mineral oil adjuvant trachoma vaccine in Taiwan school children","volume":"63","author":"Woolridge","year":"1967","journal-title":"Am J Ophthalmol"},{"issue":"23","key":"10.1016\/j.vaccine.2013.08.032_bib0175","doi-asserted-by":"crossref","first-page":"14632","DOI":"10.1128\/JVI.79.23.14632-14639.2005","article-title":"The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies","volume":"79","author":"Yim","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0180","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00357-13","article-title":"animal models for studying Chlamydia trachomatis female genital tract infection","author":"De Clercq","year":"2013","journal-title":"Infect Immun"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2013.08.032_bib0185","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1086\/425271","article-title":"Role of heard immunity in determining the effect of vaccines against sexually transmitted disease","volume":"191","author":"Garnett","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0190","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.vaccine.2013.11.007","article-title":"The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease","volume":"32","author":"Garnett","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0200","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1086\/338399","article-title":"Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunideficiency virus","volume":"34","author":"Moodley","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0205","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/OLQ.0b013e31827c5a5b","article-title":"Does bacterial vaginosis cause pelvic inflammatory disease?","volume":"40","author":"Taylor","year":"2013","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0210","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1086\/598983","article-title":"Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection","volume":"199","author":"Gray","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0215","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1473-3099(04)01148-X","article-title":"Could disease-modifying HIV vaccines cause population-level perversity?","volume":"4","author":"Smith","year":"2004","journal-title":"Lancet Infect Dis"},{"year":"2012","series-title":"Global incidence and prevalence of selected curable sexually transmitted infections \u2013 2008","author":"WHO","key":"10.1016\/j.vaccine.2013.08.032_bib0220"},{"issue":"5","key":"10.1016\/j.vaccine.2013.08.032_bib0225","first-page":"639","article-title":"Epidemiology of sexually transmitted diseases: the global picture","volume":"68","author":"De Schryver","year":"1990","journal-title":"Bull WHO"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0230","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.vaccine.2013.09.053","article-title":"Current status of syphilis vaccine development: need, challenges, and prospects","volume":"32","author":"Cameron","year":"2014","journal-title":"Vaccine"},{"issue":"9816","key":"10.1016\/j.vaccine.2013.08.032_bib0235","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(11)61750-9","article-title":"Ineffectiveness of daily standard and high-dose antiviral therapy in preventing short episodes of genital HSV-2 reactivation: three randomized, open-label cross-over trials","volume":"379","author":"Johnston","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2013.08.032_bib0240","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1089\/omi.2011.0022","article-title":"Systems vaccinomics: the road ahead for vaccinology","volume":"15","author":"Bernstein","year":"2011","journal-title":"OMICS"},{"issue":"9","key":"10.1016\/j.vaccine.2013.08.032_bib0245","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/omi.2010.0127","article-title":"Designing the next generation of vaccines for global public health","volume":"15","author":"Bagnoli","year":"2011","journal-title":"OMICS"},{"issue":"15","key":"10.1016\/j.vaccine.2013.08.032_bib0250","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.vaccine.2013.01.024","article-title":"Chlamydia trachomatis control requires a vaccine","volume":"31","author":"Brunham","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0255","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jit094","article-title":"Spontaneous resolution of genital chlamydia trachomatis infection in women and protection from reinfection","author":"Geisler","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0260","article-title":"Microbomes, sex hormones, and immune responses in the reproductive tract: challenges for vaccine development against sexually transmitted infections","author":"Brotman","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0265","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1086\/322664","article-title":"The ethical challenge of infection-inducing challenge experiments","volume":"33","author":"Miller","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2013.08.032_bib0270","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1473-3099(12)70292-X","article-title":"Human microbial challenge: the ultimate animal model","volume":"12","author":"Pollard","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0275","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fmicb.2011.00123","article-title":"Experimental gonococcal infection in male volunteers: cumulative experience with Neisseria gonorrhoeae strains FA1090 and MS11mkC","volume":"2","author":"Hobbs","year":"2011","journal-title":"Front Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2013.08.032_bib0280","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1086\/500141","article-title":"A tale of two \u03b1-herpesviruses: lessons for vaccinologists","volume":"42","author":"Rouse","year":"2006","journal-title":"Clin Infect Dis"},{"year":"2013","series-title":"International AIDS Vaccine Alliance","author":"IAVI","key":"10.1016\/j.vaccine.2013.08.032_bib0285"},{"key":"10.1016\/j.vaccine.2013.08.032_bib0290","unstructured":"Global HIV Vaccine Enterprise. http:\/\/www.vaccineenterprise.org\/."},{"key":"10.1016\/j.vaccine.2013.08.032_bib0295","unstructured":"HIV Vaccine Trials Network. <http:\/\/www.hvtn.org\/>; 2013 [accessed 28.04.13]."},{"key":"10.1016\/j.vaccine.2013.08.032_bib0310","unstructured":"OTT\/NIH. CRADAS & MTAs: http:\/\/www.ott.nih.gov\/cradas\/model_agree.aspx. [accessed 28.04.2013]."},{"key":"10.1016\/j.vaccine.2013.08.032_bib0300","unstructured":"Innovative Medicines Initiative (IMI). <www.imi.europa.eu>; 2013 [accessed 28.04.13]."},{"year":"2013","series-title":"Sexually transmitted diseases (STDs)","author":"NIH\/NIAID","key":"10.1016\/j.vaccine.2013.08.032_bib0305"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13011237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13011237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T05:38:10Z","timestamp":1563773890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13011237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":61,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0264410X13011237"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.08.032","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current barriers, challenges and opportunities for the development of effective STI vaccines: Point of view of vaccine producers, biotech companies and funding agencies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.08.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}